Global Gadoquatrane Market

Gadoquatrane Market Size, Share, Growth Analysis, By Applications(Screening and Diagnosis), By End User(Hospital, Diagnostic Centres, Specialty Clinics, Others), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35I2135 | Region: Global | Published Date: July, 2024
Pages: 219 |Tables: 62 |Figures: 75

Gadoquatrane Market Insights

Global Gadoquatrane Market was valued at USD 1.84 Billion in 2022 and is poised to grow from USD 1.94 Billion in 2023 to USD 2.92 Billion by 2031, at a CAGR of 5.28% during the forecast period (2024-2031).

MRI (Magnetic Resonance Imaging) contrast media agents are used to enhance the quality of images produced during an MRI scan. To distinguish between healthy and sick tissues, these drugs modify the magnetic characteristics of the tissue that is being scanned. Tetrameric gadoquatrane is a brand-new, extremely powerful mGBCA for MRI usage. Gadoquatrane exhibits desirable physicochemical characteristics (high relaxivity and stability, minimal protein binding) and practically the same PK profile as well-known mGBCAs on the market (rapid extracellular distribution, rapid excretion via the kidneys in an intact form).

The MRI contrast media agents demand is expected to grow significantly in the coming years, driven by the increasing prevalence of chronic diseases such as cancer, neurological disorders, and cardiovascular diseases, which require imaging for diagnosis and treatment planning. Additionally, the growing aging population and increasing demand for non-invasive diagnostic procedures are expected to further drive the market growth.

US Gadoquatrane Market is poised to grow at a sustainable CAGR for the next forecast year.

Market Snapshot - 2024-2031

Global Market Size

USD 1.84 Billion

Largest Segment

Hospital

Fastest Growth

Hospital

Growth Rate

5.28% CAGR

Global Gadoquatrane Market 2022-2030 ($ Bn)
Country Share for North America Region- 2022 (%)

To get more reports on the above market click here to Buy The Report

Gadoquatrane Market Segmental Analysis

Global Gadoquatrane Market is segmented based on Applications, End User, and region. Based on End User, the market is segmented into Hospital, Imaging Centers. Based on region the global Gadoquatrane Market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Gadoquatrane Market Analysis by End User

The hospitals segment dominated the global market in 2022. All patients who need extensive diagnostic procedures go to hospitals. Hospitals treat all chronic ailments, which explains why they have such a large market share. Additionally, the infrastructure and economy required to purchase and store these agents, as well as the volume of research activities carried out by hospitals, are only available at the hospital level.

Throughout the projection period, the imaging centers segment is anticipated to grow at the fastest rate. Many specialized facilities that could provide services like MRI are emerging as a result of growing demand for non-invasive diagnosis. To increase their clientele, these facilities are continually seeking to adopt premium and outstanding MRI and contrast agents. is therefore expected to fuel the segment's expansion during the forecast timeframe.

Global Gadoquatrane Market By End User 2022 (%), 2022 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Gadoquatrane Market Regional Insights

The North America region is anticipated to dominate the global market. Imaging analysis is in demand due to the region's rising prevalence of chronic diseases like breast cancer, cardiology, and neurological conditions. Throughout the projection period, the region is anticipated to continue to dominate. Throughout the projection period, technological advancements and the rising prevalence of chronic illnesses are expected to stimulate growth.

The quickest CAGR is anticipated to be seen in Asia Pacific during the projected period as a result of the region's growing elderly population and rising demand for cutting-edge imaging modalities. Additionally, it is projected that during the forecast period, the advanced medical imaging sector will rise in tandem with the expanding medical tourism market in Asian nations. With their fast growing healthcare service industries, availability of skilled healthcare personnel, and modern healthcare facilities and services at a lesser cost than industrialized nations, nations like India, China, and Japan are fostering growth potential.

Global Gadoquatrane Market By Geography, 2022-2030, 2024-2031
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Gadoquatrane Market Dynamics

Gadoquatrane Market Drivers

  • Gadoquatrane is a brand-new, extremely powerful mGBCA for MRI usage. The demand for MRI contrast media agents is increasing for several factors such as growing prevalence of chronic diseases, Aging population and Non-invasive diagnostic procedures. Also, technological advancements and rising healthcare expenditure are also some of the factors propelling the market demand for MRI agents. According to the report published by Investigative Radiology, Gadolinium-based contrast agents (GBCAs) have been proven to be effective and clinically useful in contrast-enhanced magnetic resonance imaging (CE-MRI) for many years. The number of treatments employing GBCAs performed globally to date has over 620 million, and the number of procedures performed annually using CE-MRI is roughly 30 million. Contrast-enhanced MRI offers significant improvements in neurological, cardiac, breast, abdominal, musculoskeletal, and vascular imaging as well as important advantages for the management of disease. The most efficient choice for MRI signal augmentation is paramagnetic gadolinium (Gd3+), which contains the greatest amount of unpaired electrons of any stable ion. In conclusion, gadoquatrane is an excellent candidate for further clinical development. Thus, the demand for MRI contrast media agents such as gadoquatrane is increasing.
  • The rising need for MRI scans for diagnosis and treatment planning is being driven by the rising prevalence of chronic diseases like cancer, cardiovascular diseases, and neurological disorders. In order to improve the clarity of these images and help doctors spot anomalies, contrast chemicals are utilized. Also, as the world's population ages, chronic diseases are more prevalent in older individuals and diagnostic imaging is more frequently needed in them. As a result, there is an increase in demand for MRI scans and contrast media. Moreover, MRI is a non-invasive diagnostic technique, negating the need for surgery or other invasive procedures. The demand for MRI scans and contrast media agents is rising as patients seek out non-invasive diagnostic solutions more frequently, which is propelling the market expansion. Moreover, improvements in MRI technology have made it feasible to create images of higher quality, which can be improved still further by the introduction of contrast media agents. The demand for these drugs has risen as a result, both in clinical and research contexts. Furthermore, governments and commercial healthcare organizations are putting more money into the infrastructure of the healthcare industry, including cutting-edge imaging technology like MRI. Patients now have easier access to MRI scans and contrast media, which is increasing demand for these goods.

Gadoquatrane Market Restraints

  • There are a number of reasons that could constrain demand and lower the price of MRI contrast media agents. Expense, safety concerns, alternative diagnostic techniques, and a move toward value-based care are a few of these causes. Moreover, the advancement of non-contrast MRI techniques may impede market expansion. Technology advancements are making non-contrast MRI procedures more precise and efficient, which requires fewer contrast agents. Moreover, MRI contrast agents can be pricey, thus some patients and healthcare professionals may choose non-contrast MRI methods to save money in light of the rising expense of healthcare. Furthermore, despite the fact that MRI contrast chemicals are typically regarded as safe, there have been a few isolated instances of negative side effects, such as allergic reactions and nephrogenic systemic fibrosis (NSF). Some individuals and healthcare professionals may decide to completely forego contrast agents as understanding of these hazards increases. Healthcare providers are also putting more of an emphasis on value-based care, which stresses providing high-quality care while lowering costs. This might result in less reliance on expensive contrast materials. Moreover, in some circumstances, ultrasonography or CT scans may be performed in place of an MRI, which further reduces the need for MRI contrast agents.

Request Free Customization of this report to help us to meet your business objectives.

Gadoquatrane Market Competitive Landscape

Currently there is only one company operating in the market. However, with the growing usage and awareness of the product, other competitors may enter the market.

Gadoquatrane Market Top Player’s Company Profiles

  • Bayer AG
  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co., Inc.
  • GlaxoSmithKline plc (GSK)
  • Roche Holding AG
  • Johnson & Johnson
  • Sanofi
  • AstraZeneca plc
  • Bristol Myers Squibb
  • AbbVie Inc.
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • Gilead Sciences, Inc.
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Celgene Corporation

Gadoquatrane Market Recent Developments

  • In November 2022, Bayer advanced its Radiology portfolio with progress on the development pipeline of new contrast agents as well as further partnerships in its digital business. The company announced the presentation of new early clinical data for gadoquatrane, Bayer’s novel macrocyclic gadolinium-based compound currently in Phase II development, at the Radiological Society of North America (RSNA) Annual Meeting.

Gadoquatrane Key Market Trends

  • Gadolinium-based contrast agents have been linked to rare but serious side effects, particularly in patients with kidney problems. As a result, there is increasing interest in the development of gadolinium-free contrast agents, such as iron oxide nanoparticles and manganese-based agents.
  • Researchers are working on developing contrast agents that can target specific tissues or cells in the body. This could allow for more precise imaging and improved diagnosis and treatment of diseases.
  • As imaging technology continues to improve, there is increasing demand for high-resolution MRI scans. This is driving the development of new contrast agents that can produce clearer images and better distinguish between different tissues.

Gadoquatrane Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.

According to our global gadoquatrane market analysis, we found that, the market possess the huge opportunities. However, a number of substitutes are available in the market which may cause threat of substitution.

Report Metric Details
Market size value in 2022 USD 1.84 Billion
Market size value in 2031 USD 2.92 Billion
Growth Rate 5.28%
Base year 2023
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Applications
    • Screening and Diagnosis
  • End User
    • Hospital, Diagnostic Centres, Specialty Clinics, Others
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Bayer AG
  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co., Inc.
  • GlaxoSmithKline plc (GSK)
  • Roche Holding AG
  • Johnson & Johnson
  • Sanofi
  • AstraZeneca plc
  • Bristol Myers Squibb
  • AbbVie Inc.
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • Gilead Sciences, Inc.
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Celgene Corporation
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Gadoquatrane Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Gadoquatrane Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Gadoquatrane Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Gadoquatrane Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Gadoquatrane Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Gadoquatrane Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Gadoquatrane Market was valued at USD 1.84 Billion in 2022 and is poised to grow from USD 1.94 Billion in 2023 to USD 2.92 Billion by 2031, at a CAGR of 5.28% during the forecast period (2024-2031).

Currently there is only one company operating in the market. However, with the growing usage and awareness of the product, other competitors may enter the market. 'Bayer AG', 'Pfizer Inc.', 'Novartis International AG', 'Merck & Co., Inc.', 'GlaxoSmithKline plc (GSK)', 'Roche Holding AG', 'Johnson & Johnson', 'Sanofi', 'AstraZeneca plc', 'Bristol Myers Squibb', 'AbbVie Inc.', 'Eli Lilly and Company', 'Teva Pharmaceutical Industries Ltd.', 'Amgen Inc.', 'Gilead Sciences, Inc.', 'Novo Nordisk A/S', 'Takeda Pharmaceutical Company Limited', 'Biogen Inc.', 'Boehringer Ingelheim International GmbH', 'Celgene Corporation'

Gadoquatrane is a brand-new, extremely powerful mGBCA for MRI usage. The demand for MRI contrast media agents is increasing for several factors such as growing prevalence of chronic diseases, Aging population and Non-invasive diagnostic procedures. Also, technological advancements and rising healthcare expenditure are also some of the factors propelling the market demand for MRI agents. According to the report published by Investigative Radiology, Gadolinium-based contrast agents (GBCAs) have been proven to be effective and clinically useful in contrast-enhanced magnetic resonance imaging (CE-MRI) for many years. The number of treatments employing GBCAs performed globally to date has over 620 million, and the number of procedures performed annually using CE-MRI is roughly 30 million. Contrast-enhanced MRI offers significant improvements in neurological, cardiac, breast, abdominal, musculoskeletal, and vascular imaging as well as important advantages for the management of disease. The most efficient choice for MRI signal augmentation is paramagnetic gadolinium (Gd3+), which contains the greatest amount of unpaired electrons of any stable ion. In conclusion, gadoquatrane is an excellent candidate for further clinical development. Thus, the demand for MRI contrast media agents such as gadoquatrane is increasing.

Gadolinium-based contrast agents have been linked to rare but serious side effects, particularly in patients with kidney problems. As a result, there is increasing interest in the development of gadolinium-free contrast agents, such as iron oxide nanoparticles and manganese-based agents.

The North America region is anticipated to dominate the market. Imaging analysis is in demand due to the region's rising prevalence of chronic diseases like breast cancer, cardiology, and neurological conditions. Throughout the projection period, the region is anticipated to continue to dominate. Throughout the projection period, technological advancements and the rising prevalence of chronic illnesses are expected to stimulate growth.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Gadoquatrane Market

Product ID: SQMIG35I2135

$5,300
BUY NOW GET FREE SAMPLE